Statistically significant but clinically unimportant: a systematic review and meta-analysis of the analgesic benefits of erector spinae plane block following breast cancer surgery.


Journal

Regional anesthesia and pain medicine
ISSN: 1532-8651
Titre abrégé: Reg Anesth Pain Med
Pays: England
ID NLM: 9804508

Informations de publication

Date de publication:
01 2021
Historique:
received: 14 07 2020
revised: 11 08 2020
accepted: 21 08 2020
pubmed: 11 11 2020
medline: 29 6 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

The novel erector spinae plane block (ESPB) has been reported to provide important postoperative analgesic benefits following a variety of truncal and abdominal surgical procedures. However, evidence of its analgesic efficacy following breast cancer surgery, compared with parenteral analgesia, is unclear. This meta-analysis evaluates the analgesic benefits of adding ESPB to parenteral analgesia following breast cancer surgery.Databases were searched for breast tumor resection trials comparing ESPB to parenteral analgesia. The two co-primary outcomes examined were 24-hour postoperative oral morphine equivalent consumption and area-under-curve of rest pain scores. We considered reductions equivalent to 3.3 cm.h and 30 mg oral morphine in the first 24 hours postoperatively for the two co-primary outcomes, respectively, to be clinically important. We also assessed opioid-related side effects and long-term outcomes, including health-related quality of life, persistent postsurgical pain and opioid dependence. Results were pooled using random effects modeling.Twelve trials (699 patients) were analyzed. Moderate quality evidence suggested that ESPB decreased 24-hour morphine consumption and area-under-curve of rest pain by a mean difference (95% CI) of -17.60 mg (-24.27 to -10.93) and -2.74 cm.h (-3.09 to -2.39), respectively; but these differences were not clinically important. High-quality evidence suggested that ESPB decreased opioid-related side effects compared with parenteral analgesia by an OR (95% CI) of 0.43 (0.28 to 0.66). None of the studies evaluated long-term block benefits.Adding ESPB to parenteral analgesia provides statistically significant but clinically unimportant short-term benefits following breast cancer surgery. Current evidence does not support routine use of ESPB. Given the very modest short-term benefits and risk of complications, the block should be considered on a case-by-case basis.

Identifiants

pubmed: 33168651
pii: rapm-2020-101917
doi: 10.1136/rapm-2020-101917
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-12

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© American Society of Regional Anesthesia & Pain Medicine 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Nasir Hussain (N)

Anesthesiology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Richard Brull (R)

Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.

Jordan Noble (J)

Anesthesiology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Tristan Weaver (T)

Anesthesiology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Michael Essandoh (M)

Anesthesiology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Colin Jl McCartney (CJ)

Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Faraj W Abdallah (FW)

Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada mank_abda@yahoo.ca.
Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH